Zai Lab Ltd (NAS:ZLAB)
$ 20.16 0.15 (0.75%) Market Cap: 1.98 Bil Enterprise Value: 1.42 Bil PE Ratio: 0 PB Ratio: 2.57 GF Score: 71/100

Zai Lab Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 01:40PM GMT
Release Date Price: $68.99 (-5.00%)
Ziyi Chen
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Good morning, everyone. Thank you for joining today's Zai Lab session at our Global Healthcare Conference. This is Ziyi Chen, China healthcare analyst at Goldman Sachs.

Today joining us are Zai Lab's Co-Founder, Chairperson and CEO, Dr. Samantha Du; CFO, Billy Cho; and Jonathan Wang, Head of BD and IR team. Thank you all for attending these sessions.

Questions & Answers

Ziyi Chen;Ying Du<
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Just to start the session, here's one specific question that probably most investors will be highly interested is the impact of COVID-19. We actually start this question for each of the session. So could you please give us some thoughts on the impact on clinical trials, BD activities and also the commercial launch of ZEJULA, Optune in China in this environment, particularly in first quarter? And how we actually track the recovery of everything, gradually back to normal in May, June? So any thoughts on that?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot